Multiplexed Immunofluorescence


Multiplexed Immunofluorescence: a complete view of tumor behavior

Utilizing deep learning and advanced cell classification algorithms, multiplexed immunofluorescence spatial analysis uncovers the complex interplay between multitudes of immuno-oncology biomarkers and provides complete analysis of the tumor microenvironment. Multiplexed immunofluorescence has emerged as an effective and proficient approach to simultaneously identify specific proteins and immune cell types, to determine the spatial distribution and activation state of immune cells, as well as the expression of immune modulators, all at the same time. This method is highly beneficial for exploring immune evasion mechanisms and finding potential biomarkers that allow researchers to assess the mechanism of action and predict and monitor drug response.

NeoGenomics’ Pharma Services offer two multiplex immunofluorescence platforms: MultiOmyx and Vectra® Polaris


MultiOmyx is a proprietary, high-order multiplexing methodology that enables visualization and characterization of up to 60 proteins in a single FFPE tissue section.

High order ≥ 7 plex
Comprehensive analysis of tumor biology
Deep & precise immuno-profiling

Learn More

Vectra® Polaris™

Vectra® Polaris is an automated system that allows simultaneous detection of 2-6 different markers from a single FFPE tissue slide which would provide a streamlined workflow for implementing refined low-order multiplex panel sets.

Low order 2-6 plex
High-throughput & faster TAT
Assay transfer & validation

Learn More

Latest Publications:

View All Publications

Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle TICA

Nov 13, 2021

Multiplex Immunofluorescence Assay, MultiOmyx: Detection and deep profiling of immune cells in HBV-infected liver biopsies

World Vaccine Congress
Oct 19, 2021

Co-detection of a tumor-infiltrating lymphocyte immunofluorescence (IF) panel and cytokine RNA in-situ hybridization (ISH) markers in non-small cell lung cancer (NSCLC) tumor microenvironment using combined MultiOmyx and RNAScope platforms

Presented at AACR 2021
Apr 15, 2021

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients